{"meshTagsMajor":["Mutation"],"meshTags":["Antineoplastic Combined Chemotherapy Protocols","Breast Neoplasms","Drug Resistance, Neoplasm","Female","Humans","Mutation","Neoadjuvant Therapy","Phosphatidylinositol 3-Kinases","Receptor, ErbB-2"],"meshMinor":["Antineoplastic Combined Chemotherapy Protocols","Breast Neoplasms","Drug Resistance, Neoplasm","Female","Humans","Neoadjuvant Therapy","Phosphatidylinositol 3-Kinases","Receptor, ErbB-2"],"genes":["PIK3CA","PIK3CA"],"organisms":["6755"],"publicationTypes":["News"],"abstract":"Women with HER2-postive, hormone receptor-positive breast cancer and one or more mutations in PIK3CA were less likely to benefit from neoadjuvant chemotherapy and HER2-targeted therapies than those without a mutation, according to study results presented on December 12 at the 2013 San Antonio Breast Cancer Symposium in Texas. ","title":"PIK3CA mutation predicts resistance to breast cancer therapy.","pubmedId":"24501315"}